• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark

    Reed-Lane Facility Virtual Tour
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Almac Group

    Alcami

    Emergent BioSolutions

    Cytovance Biologics
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Alcami

    Syngene

    Reed-Lane

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Expert's Opinion

    Know the Challenges of Biosimilar Manufacturing

    Best Practices for a Competitive Market

    Know the Challenges of Biosimilar Manufacturing
    Related CONTENT
    • Manufacturing Equipment Trends
    • Novartis Invests in Credence MedSystems
    • Schreiner MediPharm Joins DoseID Consortium
    • Reed-Lane Adds Second Track & Trace Cartoning Line
    • RedHill Biopharma Ramps-Up Manufacturing of Opaganib
    Jerry Martin, Pharmaceutical and Life Sciences Consultant to PMMI, and, Dr. Michiel Ultee, Principal, Ulteemit BioConsulting, LLC 04.11.18
    Interest in biosimilar protein drugs continues to grow and pharmaceutical manufacturers are racing to patent new drug formulations in order to survive in an evolving market.[1] Biosimilars are receiving a lot of attention due to the perceived cost-savings that consumers hope to gain and opportunities for alternative pharmaceutical manufacturers to enter both established and emerging markets. The characteristic protein makeup of biosimilars, however, requires strict and careful manufacturing practices in order to maintain safety and satisfy U.S. Food and Drug Administration (FDA) regulations, all while yielding a return on investment.

    Pharmaceutical manufacturers must prepare themselves for some of the challenges that lie ahead for the biosimilars market. To help the industry avoid pitfalls, we spoke with two industry experts to weigh in on the important challenges pharmaceutical companies can anticipate in the manufacturing and packaging of biosimilars.

    In order to reduce patient costs, pharmaceutical manufacturers first turned to developing small molecule generics, a widely accepted identical version of brand name drugs. While that continues, manufacturers are now also turning their eyes toward developing biosimilars of large molecule biotechnology drugs to take advantage of developmental cost benefits, like avoiding research discovery and initial clinical safety and efficacy testing costs. However, they often do not have the same flexibility to save production costs like many generic manufacturers. Some major challenges biosimilar manufacturers will face in processing and packaging are the variability of large-molecules and the necessity of providing FDA with sufficient evidence to prove clinical safety.
     
    The conditions in which cells are cultured can ultimately alter the molecular structure and clinical behavior of biosimilars, and potentially introduce impurities, traces of cell proteins, DNA and contaminating viruses. Additionally, because the molecular structures of biosimilars are so complex, we currently lack the proper analytical tools to accurately identify the difference between the biosimilar and the original therapeutic protein (hence the term biosimilar versus bio-identical). While we can show a high degree of similarity in a molecule’s chemical and biological identity, we still need to demonstrate that each biosimilar can act as a pharmaceutical drug with the same amount of clinical safety and effectiveness as the original. All of these factors could significantly slow down the timeline to approval and production. Lastly, as biosimilar developers target more complex proteins, development costs will likely rise as manufacturers face regulatory challenges to prove high levels of similarity.

    Best Practices for a Competitive Market
    A major payoff of investing in biosimilar manufacturing is that you can get to market faster than a new innovator biopharmaceutical. Some friendly advice would be to start three to five years before a patent expires. A biosimilar manufacturer will also want to purchase large quantities of the innovator product because they will need various samples of different batches to truly understand the range of allowed variability in analytical properties. Having a strong analytical system will also be paramount in determining the characterization of the biosimilar; for example, quality mass spectrometer and electrophoresis instrumentation for structure and glycoform testing.

     
    In order to compete on price, biosimilar manufacturers should select a cell line with high specific productivity as well as the ability to grow to high cell densities, thereby yielding the highest amount or titer in each bioreactor run. In addition to these cell-line features, biosimilar manufacturers will want to develop an efficient downstream process to purify the biosimilar from the crude cell harvest. A robust cold chain is needed as well to handle the bulk drug and drug product because of the temperature sensitivities of biological products. This includes investment in temperature monitors to ensure that products maintain ultra-cold temperatures. Lastly, biosimilar manufacturers may want to consider packaging innovations because this is an area where the FDA allows some latitude. For example, an innovator drug that is stored in a vial could instead be packaged in a pre-filled syringe, resulting in greater convenience and reduced agitation of the protein solution during shipping and handling.

    [1] https://www.bloomberg.com/gadfly/articles/2017-02-24/allergan-biosimilar-pullback-won-t-be-the-last

     


    Jerold Martin

    PMMI, The Association for Packaging and Processing Technologies, represents the voice of more than 800 North American manufacturers and suppliers of equipment, components and materials as well as providers of related equipment and services to the packaging and processing industry. We work to advance a variety of industries by connecting consumer goods companies with manufacturing solutions through PACK EXPO portfolio of trade shows, leading trade media and a wide range of resources to empower our members.



    Dr. Michiel Ultee
    Related Searches
    • production
    • discovery
    • quality
    • biosimilars
    Suggested For You
    Manufacturing Equipment Trends Manufacturing Equipment Trends
    Novartis Invests in Credence MedSystems Novartis Invests in Credence MedSystems
    Schreiner MediPharm Joins DoseID Consortium Schreiner MediPharm Joins DoseID Consortium
    Reed-Lane Adds Second Track & Trace Cartoning Line Reed-Lane Adds Second Track & Trace Cartoning Line
    RedHill Biopharma Ramps-Up Manufacturing of Opaganib RedHill Biopharma Ramps-Up Manufacturing of Opaganib
    Vetio Animal Health Vetio Animal Health
    TraceLink Expands Supply Chain Solutions Portfolio TraceLink Expands Supply Chain Solutions Portfolio
    FDA Approves Grifols FDA Approves Grifols' Facility for Production of Recombinant Proteins
    Are Indian Generic Firms Improving Compliance? Are Indian Generic Firms Improving Compliance?
    FDA Grants Soleno FTD FDA Grants Soleno FTD
    Rockwell Medical Announces FDA Approval Rockwell Medical Announces FDA Approval
    18	ALLERGAN 18 ALLERGAN
    TraceLink Unveils Product Information Manager TraceLink Unveils Product Information Manager
    FDA Approves GW Pharma FDA Approves GW Pharma's Epidiolex
    Semi-Solids: A Regulatory Perspective Semi-Solids: A Regulatory Perspective

    Related Expert's Opinion

    • Biosimilars
      Navigating Uncertainty in Biosimilar Drug Development

      Navigating Uncertainty in Biosimilar Drug Development

      Bryan Katz of Syneos Health and Brittany Scott of Addison Whitney share insights from DIA
      Bryan Katz, Vice President Integrated Solutions, Syneos Health and Brittany Scott, Creative Director, Addison Whitney, a Syneos Health company 07.11.18

    • Biosimilars | Drug Development
      Differentiating in the Biosimilar Market: Surviving the Cost of Entry

      Differentiating in the Biosimilar Market: Surviving the Cost of Entry

      Companies need to improve customer experience, produce additional evidence, and create valuable engagement with stakeholders
      Michael Turner and Magnus Franzen, Life Sciences Experts, PA Consulting Group 03.01.18

    • Bioanalytical Services | Biosimilars
      The Analytical Challenges of the Biosimilar Boom

      The Analytical Challenges of the Biosimilar Boom

      The growing biosimilar industry and its implications on the current drug market
      Mario DiPaola, Senior Scientific Director, Charles River Laboratories 07.03.17


    • Analytical Services | Bioanalytical Services | Bioassay Development | Biosimilars | Laboratory Testing
      Qualification of an Assay

      Qualification of an Assay

      With applications for investigating functional comparability of an originator and biosimilar
      Nicolas Fourrier, Director Biomarker and Biopharmaceutical Testing, SGS; Abhishek Saharia, Director of Cell-Based Assays & Biologics, DiscoverX; Fiona Greer, Global Director, Biopharma Services Development, Life Sciences, SGS 11.30.16

    • Analytical Services | APIs | Biosimilars | Drug Development
      How to Build Better Proteins

      How to Build Better Proteins

      Advancing the next generation of biologics
      Aileen Ruff, Catalent 01.13.16

    • Biosimilars | Drug Development | Logistics | Validation

      How Pharma Manufacturers Can Gain a Competitive Edge with Advanced Pricing Data and Analytics

      Andrew Hanhauser of Alliance Life Sciences addresses ways to optimize pricing strategies
      Andrew Hanhauser, Manager, Global Pricing and Market Access, Alliance Life Sciences 11.02.15


    • Biosimilars | Drug Delivery | Drug Development
      Packaging Predictions for Pharma/Biopharma in 2015

      Packaging Predictions for Pharma/Biopharma in 2015

      Growth of biologics impacts parameters for optimal drug delivery
      Graham Reynolds, Vice President of Marketing & Innovation, West Pharmaceutical Services, Inc. 01.20.15

    • Biosimilars

      Unlocking the Potential of Biosimilars

      Biosimilars face far more demanding clinical, market access, manufacturing and sales and marketing requirements, than small-molecule generics did.
      Gurpreet Sandhu, Reva Pharmaceuticals 06.18.14

    • Biosimilars

      Biosimilars and Biobetters: From Basic Similarity to Simplified Innovation

      Everyone talks about biosimilarity, but it’s clarifying the differences between biosimilars, biobetters and me-too products that will be critical to biological innovation and pricing
      Fereshteh Barei, Dauphine University 06.18.14


    • Bio News | Bioassay Development | Biologics, Proteins, Vaccines | Biosimilars | Capsules | Clinical Trial Materials | Clinical Trials | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Methods Development | Parenterals | Process Development | R&D | Regulatory Affairs | Toxicology | Trials & Filings

      The U.S. Biosimilar Approval Pathway

      Policy precedes science
      David Shoemaker, Ph.D., Senior Vice President, R&D, Rho 01.08.14

    • Bio News | Biologics, Proteins, Vaccines | Biosimilars | GMPs/GCPs | Inspections | Regulatory Affairs

      FDA Issues Draft Guidances on Biosimilars

      An initial take on the Agency's proposal for biosimilars
      Tim Clark 02.29.12

    • Bio News | Biosimilars | Promotions & Moves

      A $500 Million Blunder?

      Was the departure of Lonza's CEO too hasty?
      Andrew Badrot 02.08.12


    • Biologics, Proteins, Vaccines | Biosimilars | Clinical Trials | CRO News | GMPs/GCPs | Information Technology | Inspections | Preclinical Outsourcing | Regulatory Affairs

      PPD Goes Private: What's Next?

      Acquired by PE firms, the CRO looks to the future
      Lee Karras 12.14.11

    • Biologics, Proteins, Vaccines | Biosimilars | Clinical Trials

      Why BI’s Biosimilar Announcement Just Makes Sense

      Unique skillsets and assets explain why BI is primed for success in this burgeoning market
      Andrew Badrot 10.05.11

    • Biosimilars | Clinical Trials | Drug Development

      The Impact of the FDA Hearing on the Growing Biosimilars Market

      New trials are necessary for patient safety
      05.11.11

    Trending
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Reed-Lane Facility Virtual Tour
    Breaking News
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Aptamer Extends Collaboration with AstraZeneca
    • Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Thymoquinone Inhibits Viral Infection in In Vitro Settings, New Study Finds
    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President, COO
    Ashland Completes Expansion, Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcoVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex CFO Announces Retirement
    New AI-Based Tool Developed for Coronary Artery Analysis, Intervention Planning
    First Reported Use of Pulse Biosciences' CellFX System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AGC Biologics Expands Cell and Gene Facility in Italy
    Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Ulta Beauty Opens in Herald Square
    Elizabeth Arden Taps Sui He as Global Brand Ambassador
    Natura &Co Outperforms the Global Market in Q4 2020
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Indie Beauty Innovators Wanted
    Cosmetic Chemists Seek Mentors
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex America welcomes Maggie Naberezny to sales team
    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Bioventus Appoints Managing Director, China and Asia Pacific
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login